3SBio Inc.
VC Fund
Shenyang, China
3SBio Inc. is a VC fund in Shenyang focused on Medical and Therapeutics. 3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.Withheadquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries 3SBio Inc. invests in
Stages 3SBio Inc. invests in
Countries 3SBio Inc. invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dr. Jing Lou
|
|||
Investment Focus
Industry
- Medical 4 (67%)
- Therapeutics 4 (67%)
- Biotechnology 4 (67%)
- Biopharma 2 (33%)
- Health Care 2 (33%)
Stage
- Series B 3 (50%)
- Series A 2 (33%)
- Funding Round 1 (17%)
Country
- United States 3 (50%)
- China 1 (17%)
- Switzerland 1 (17%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Dr. Jing Lou
Chairman of the board of directors and Chief Executive Officer, Director /Founder
|
Chairman of the board of directors and Chief Executive Officer, Director /Founder | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NK CellTech
|
NK CellTech is a biotechnology company that specializes in the development of innovative technologies for the treatment of NK cell therapy. | Series A / Nov 22, 2024 | |
|
C Ray Therapeutics
|
C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020. | $100M / Series A / Nov 16, 2024 | |
Allorion Therapeutics
|
Allorion Therapeutics is a small molecule therapeutic development company that focuses on cancer and autoimmune illnesses. Allorion operates two locations in Natick, Massachusetts, and Guangzhou, China. | $50M / Series B / Mar 09, 2023 | |
Numab
|
Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases such as chronic inflammation and cancer. It features a plug-and-play platform that substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics. | Series B / Dec 12, 2019 | |
Verseau Therapeutics
|
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients fromimmunotherapy. | $50M / Oct 21, 2019 | |
Refuge Biotechnologies
|
Refuge is a cancer immunotherapy company leveraging synthetic biology and gene engineering to unlock the full promise of cell therapies. We create cell therapies that sense their surroundings and conditionally activate or repress multiple genes simultaneously – resulting in more potent and targeted treatments beyond a single target and function. | $25M / Series B / May 02, 2018 |
Co-Investors
INCE Capital
2 deals together
20/20 HealthCare Partners
1 deal together
3E Bioventures
1 deal together
Alexandria Venture Investments
1 deal together
DHVC
1 deal together
Eisai
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does 3SBio Inc. invest in?
3SBio Inc. invests primarily in Medical, Therapeutics and Biotechnology startups, most often at Series B and Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact 3SBio Inc.?
Public channels for 3SBio Inc. include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 3SBio Inc.?
The team at 3SBio Inc. includes Dr. Jing Lou (Chairman of the board of directors and Chief Executive Officer, Director /Founder). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
